{"meta":{"totalResults":3,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"ABT-700"},{"type":"CASRegistryName","name":"1781223-80-0"},{"type":"Synonym","name":"Anti-c-Met Monoclonal Antibody ABT-700"}],"definition":{"html":"An immunoglobulin G1 (IgG1) humanized monoclonal antibody directed against human hepatocyte growth factor receptor (HGFR or c-Met), with potential antineoplastic activity. Telisotuzumab binds to c-Met, thereby preventing both c-Met binding to its ligand, HGF and the subsequent activation of the HGF/c-Met signaling pathway. This may cause cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.","text":"An immunoglobulin G1 (IgG1) humanized monoclonal antibody directed against human hepatocyte growth factor receptor (HGFR or c-Met), with potential antineoplastic activity. Telisotuzumab binds to c-Met, thereby preventing both c-Met binding to its ligand, HGF and the subsequent activation of the HGF/c-Met signaling pathway. This may cause cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis."},"drugInfoSummaryLink":null,"nciConceptId":"C106262","nciConceptName":"Telisotuzumab","termId":717765,"name":"Telisotuzumab","firstLetter":"t","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"telisotuzumab"},{"aliases":[{"type":"CodeName","name":"ABBV400"},{"type":"CodeName","name":"ABBV 400"},{"type":"CodeName","name":"ABBV-400"},{"type":"Synonym","name":"c-Met ADC ABBV-400"},{"type":"Synonym","name":"ADC ABBV-400"},{"type":"Synonym","name":"anti-c-Met antibody-drug conjugate ABBV-400"},{"type":"CASRegistryName","name":"2850366-99-1"},{"type":"Synonym","name":"anti-c-Met ADC ABBV-400"}],"definition":{"html":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the tumor-associated antigen (TAA) proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) linked to an undisclosed topoisomerase inhibitor, with potential antineoplastic activity. Upon intravenous administration of anti-c-Met ADC ABBV-400, the monoclonal antibody moiety targets and binds to c-Met expressed on tumor cells. Upon binding and internalization, the topoisomerase inhibitor is released, which binds to and inhibits topoisomerase, thereby inhibiting DNA replication and killing the c-Met-expressing cancer cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis.","text":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the tumor-associated antigen (TAA) proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) linked to an undisclosed topoisomerase inhibitor, with potential antineoplastic activity. Upon intravenous administration of anti-c-Met ADC ABBV-400, the monoclonal antibody moiety targets and binds to c-Met expressed on tumor cells. Upon binding and internalization, the topoisomerase inhibitor is released, which binds to and inhibits topoisomerase, thereby inhibiting DNA replication and killing the c-Met-expressing cancer cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis."},"drugInfoSummaryLink":null,"nciConceptId":"C184368","nciConceptName":"Telisotuzumab Adizutecan","termId":806804,"name":"telisotuzumab adizutecan","firstLetter":"t","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"telisotuzumab-adizutecan"},{"aliases":[{"type":"CodeName","name":"ABBV-399"},{"type":"CodeName","name":"ABBV 399"},{"type":"CodeName","name":"ABT 399"},{"type":"CodeName","name":"ABT-399"},{"type":"Synonym","name":"ABT-700-VCMMAE"},{"type":"CASRegistryName","name":"1714088-51-3"}],"definition":{"html":"An antibody-drug conjugate (ADC) composed of telisotuzumab, a monoclonal antibody against the tumor-associated antigen (TAA) and proto-oncogene, c-Met receptor tyrosine kinase (c-Met; MET; hepatocyte growth factor receptor; HGFR) conjugated to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline (vc) peptide linker (vc-MMAE; vedotin), with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of telisotuzumab vedotin targets and binds to c-Met expressed on tumor cells. Upon binding, internalization and enzymatic cleavage, the cytotoxic agent MMAE is released into the cytosol. MMAE binds to tubulin and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. This kills the c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis.","text":"An antibody-drug conjugate (ADC) composed of telisotuzumab, a monoclonal antibody against the tumor-associated antigen (TAA) and proto-oncogene, c-Met receptor tyrosine kinase (c-Met; MET; hepatocyte growth factor receptor; HGFR) conjugated to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline (vc) peptide linker (vc-MMAE; vedotin), with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of telisotuzumab vedotin targets and binds to c-Met expressed on tumor cells. Upon binding, internalization and enzymatic cleavage, the cytotoxic agent MMAE is released into the cytosol. MMAE binds to tubulin and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. This kills the c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis."},"drugInfoSummaryLink":null,"nciConceptId":"C118571","nciConceptName":"Telisotuzumab Vedotin","termId":759579,"name":"telisotuzumab vedotin","firstLetter":"t","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"telisotuzumab-vedotin"}],"links":null}